[Modern Individualized Diagnostics and Treatment of Non-small Cell Lung Cancer]

Overview

Journal Chirurgie (Heidelb)

Specialty General Surgery

Date 2024 Feb 20

PMID 38376521

Authors

Hauke Winter

Martin Eichhorn

Florian Eichhorn

Matthias Grott

Affiliations

Soon will be listed here.

Abstract

Approximately one half of patients with non-small cell lung cancer (NSCLC) are diagnosed at resectable tumor stages (I-IIIA), which can potentially be curatively treated. In the early tumor stages (tumor diameter ≤2 cm) sublobar resection (segmentectomy or atypical wedge resection) leads to a 5‑year long-term survival comparable to lobectomy. The use of immunotherapy, especially within the framework of neoadjuvant treatment, is anticipated to change the surgical treatment of NSCLC in the future. With the introduction of lung cancer screening for certain risk groups in Germany planned for 2024, lung tumors can be expected to be diagnosed at earlier stages and more frequently curatively treated. This article provides an overview of the potential impact of lung cancer screening, modern minimally invasive surgical techniques and neoadjuvant treatment concepts for the surgical treatment of NSCLC.

References

Lee J, McNamee C, Toloza E, Negrao M, Lin J, Shum E . Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives. J Thorac Oncol. 2023; 18(11):1458-1477. PMC: 11040203. DOI: 10.1016/j.jtho.2023.07.006. View

Kalata S, Mollberg N, He C, Clark M, Theurer P, Chang A . The Role of Lung Cancer Surgical Technique on Lymph Node Sampling and Pathologic Nodal Upstaging. Ann Thorac Surg. 2022; 115(5):1238-1245. DOI: 10.1016/j.athoracsur.2022.09.040. View

Terra R, Leite P, Dela Vega A . Global status of the robotic thoracic surgery. J Thorac Dis. 2021; 13(10):6123-6128. PMC: 8575837. DOI: 10.21037/jtd-19-3271. View

Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K . Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022; 399(10335):1607-1617. DOI: 10.1016/S0140-6736(21)02333-3. View

Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D . Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. N Engl J Med. 2023; 388(6):489-498. PMC: 10036605. DOI: 10.1056/NEJMoa2212083. View

Forde P, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad M . Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022; 386(21):1973-1985. PMC: 9844511. DOI: 10.1056/NEJMoa2202170. View

Schutte W, Gutz S, Nehls W, Blum T, Bruckl W, Buttmann-Schweiger N . [Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer - Interdisciplinary Guideline of the German Respiratory Society and the German Cancer Society - Abridged Version]. Pneumologie. 2023; 77(10):671-813. DOI: 10.1055/a-2029-0134. View

Ginsberg R, Rubinstein L . Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995; 60(3):615-22; discussion 622-3. DOI: 10.1016/0003-4975(95)00537-u. View

Suzuki K, Koike T, Asakawa T, Kusumoto M, Asamura H, Nagai K . A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201). J Thorac Oncol. 2011; 6(4):751-6. DOI: 10.1097/JTO.0b013e31821038ab. View

10.

KIRBY T, Rice T . Thoracoscopic lobectomy. Ann Thorac Surg. 1993; 56(3):784-6. DOI: 10.1016/0003-4975(93)90980-v. View

11.

Walker W, Carnochan F, Pugh G . Thoracoscopic pulmonary lobectomy. Early operative experience and preliminary clinical results. J Thorac Cardiovasc Surg. 1993; 106(6):1111-7. View

12.

Mangiameli G, Cioffi U, Testori A . Lung Cancer Treatment: From Tradition to Innovation. Front Oncol. 2022; 12:858242. PMC: 9184755. DOI: 10.3389/fonc.2022.858242. View

13.

Oh J, Lee J, Yoon E, Jeong S, Kim S, Chon Y . Regular Alpha-Fetoprotein Tests Boost Curative Treatment and Survival for Hepatocellular Carcinoma Patients in an Endemic Area. Cancers (Basel). 2024; 16(1). PMC: 10778056. DOI: 10.3390/cancers16010150. View

14.

Falcoz P, Puyraveau M, Thomas P, Decaluwe H, Hurtgen M, Petersen R . Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer: a propensity-matched analysis of outcome from the European Society of Thoracic Surgeon database. Eur J Cardiothorac Surg. 2015; 49(2):602-9. DOI: 10.1093/ejcts/ezv154. View

15.

Louie B, Wilson J, Kim S, Cerfolio R, Park B, Farivar A . Comparison of Video-Assisted Thoracoscopic Surgery and Robotic Approaches for Clinical Stage I and Stage II Non-Small Cell Lung Cancer Using The Society of Thoracic Surgeons Database. Ann Thorac Surg. 2016; 102(3):917-924. PMC: 5198574. DOI: 10.1016/j.athoracsur.2016.03.032. View

16.

Oh D, Reddy R, Gorrepati M, Mehendale S, Reed M . Robotic-Assisted, Video-Assisted Thoracoscopic and Open Lobectomy: Propensity-Matched Analysis of Recent Premier Data. Ann Thorac Surg. 2017; 104(5):1733-1740. DOI: 10.1016/j.athoracsur.2017.06.020. View

17.

Felip E, Altorki N, Zhou C, Csoszi T, Vynnychenko I, Goloborodko O . Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021; 398(10308):1344-1357. DOI: 10.1016/S0140-6736(21)02098-5. View

18.

Wu Y, Tsuboi M, He J, John T, Grohe C, Majem M . Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020; 383(18):1711-1723. DOI: 10.1056/NEJMoa2027071. View

19.

Tsuboi M, Herbst R, John T, Kato T, Majem M, Grohe C . Overall Survival with Osimertinib in Resected -Mutated NSCLC. N Engl J Med. 2023; 389(2):137-147. DOI: 10.1056/NEJMoa2304594. View

20.

Sanber K, Rosner S, Forde P, Marrone K . Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer. BioDrugs. 2023; 37(6):775-791. DOI: 10.1007/s40259-023-00614-5. View